Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation-Reference-Cited by-同舟云学术

Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation

Published:2018-11-17 Issue:2 Volume:109 Page:197-205
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ueda Tomoaki,Maeda Tetsuo,Kusakabe Shinsuke,Fujita Jiro,Fukushima Kentaro,Yokota Takafumi,Shibayama Hirohiko,Tomiyama Yoshiaki,Kanakura Yuzuru

Funder

Otsuka Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-018-2562-8/fulltext.html

Reference32 articles.

1. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011;17(10):1490–6.

2. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–64.

3. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant. 2008;41(11):935–40.

4. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525–36.

5. Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplantat for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2(16):2095–103.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation;Transplantation Proceedings;2024-09

2. Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study;eJHaem;2024-07-08

3. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study;Bone Marrow Transplantation;2024-02-08

4. Fludarabine Melphalan, Reduced-Dose Busulfan Versus Fludarabine, Melphalan, Full-Dose Busulfan in Patients Receiving Cord Blood Transplantation;2024

5. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients;Transplantation and Cellular Therapy;2023-08